隔日与每周一次保留尿道的 Sicherheit 前列腺立体定向体部放疗:随机2期试验5年结果
该研究为前瞻性多中心2期随机试验,纳入170例cT1c-3aN0M0局限性前列腺癌患者,随机接受36.25 Gy/5次(尿道每次6.5 Gy)隔日(A组,n=84)或每周一次(B组,n=86)照射。5年随访显示两组≥2级泌尿生殖毒性无进展生存率分别为75.9%和76.1%(P=.945),≥2级胃肠毒性无进展生存率分别为89%和92%(P=.596),生化无复发生存率分别为92.2%和93%(P=.13)。结论认为10%尿道剂量降低对排尿功能和生活质量影响轻微,隔日与每周一次方案相似,生化控制令人鼓舞,但可能需要更长随访评估总治疗时间对疾病结局的真实价值。
要点
- 5年≥2级泌尿生殖毒性无进展生存率隔日组75.9% vs 每周一次组76.1%(P=.945)。
- 5年≥2级胃肠毒性无进展生存率隔日组89% vs 每周一次组92%(P=.596)。
- 5年生化无复发生存率隔日组92.2% vs 每周一次组93%(P=.13)。
核心结论
- 前列腺癌立体定向体部放疗中尿道剂量降低10%对排尿功能和生活质量影响轻微,无论隔日还是每周一次分割方案。
- 迄今生化控制令人鼓舞且两组相似,但可能需要更长随访评估总治疗时间对疾病结局的真实价值。
研究设计与样本
- 前瞻性、多中心、2期随机试验,2012年至2015年纳入9家欧洲机构的170例cT1c-3aN0M0前列腺癌患者。
- 随机分为隔日组(A组,n=84)和每周一次组(B组,n=86),均接受36.25 Gy/5次,尿道每次6.5 Gy。
- 最终分析纳入165例接受治疗的患者(A组n=82,B组n=83);A组中位随访78个月(四分位距66-89个月),B组77个月(四分位距66-82个月)。
主要发现
- 急性毒性(NCI CTCAE 4.03量表)轻微或无,两组间无差异。
- 5年≥2级泌尿生殖毒性无进展生存率A组75.9% vs B组76.1%(P=.945)。
- 5年≥2级胃肠毒性无进展生存率A组89% vs B组92%(P=.596)。
- 5年随访时两组EORTC QLQ-PR25在泌尿生殖、胃肠和性功能领域评分较基线均无变化。
- 末次随访时A组14例、B组7例出现生化失败,5年生化无复发生存率A组92.2% vs B组93%(P=.13)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出可能需要更长随访评估总治疗时间对疾病结局的真实价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The objective of this study was to present the 5-year results from a prospective, multicenter, phase 2 randomized trial of every-other-day (EOD) versus once-a-week (QW) urethra-sparing stereotactic body radiation therapy for localized prostate cancer. METHODS AND MATERIALS: Between 2012 and 2015, 170 patients with cT1c-3aN0M0 prostate cancer from 9 European institutions were randomized to 36.25 Gy in 5 fractions (6.5 Gy/fraction to the urethra) delivered either EOD (arm A, n = 84) or QW (arm B, n = 86). The median follow-up was 78 months (interquartile range, 66-89 months) and 77 months (interquartile range, 66-82 months) for arms A and B, respectively. RESULTS: Among the 165 patients treated and retained for the final analysis (arm A, n = 82; arm B, n = 83), acute toxicity (National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 scale) was mild or absent, with no differences between arms. The 5-year grade 2 or greater genitourinary toxicity-free survival was 75.9% and 76.1% for arms A and B, respectively (P = .945), whereas the 5-year grade 2 or greater gastrointestinal toxicity-free survival was 89% and 92% for arms A and B, respectively (P = .596). No changes in European Organisation for Research and Treatment of Cancer QLQ-PR25 scores were observed in both arms for genitourinary, gastrointestinal, and sexual domains at 5-year follow-up compared with baseline. At the last follow-up, biochemical failure was observed in 14 patients in the EOD arm and in 7 patients in the QW arm, with a 5-year biochemical relapse-free survival rate of 92.2% and 93% for arms A and B, respectively (P = .13). CONCLUSIONS: Stereotactic body radiation therapy for prostate cancer with a 10% dose reduction to urethra was associated with a minimal effect on urinary function and quality of life regardless of an EOD or QW fractionation schedule. Biochemical control so far has been encouraging and much alike in both study arms, although longer follow-up is probably needed to assess the true value of overall treatment time on disease outcome.
引用
- Zilli T, Jorcano S, Bral S, et al. Every-Other-Day Versus Once-a-Week Urethra-Sparing Prostate Stereotactic Body Radiation Therapy: 5-Year Results of a Randomized Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 37001763. doi:10.1016/j.ijrobp.2023.03.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。